BRAF and metastatic neoplasm: Numerous studies have demonstrated that about half patients with advanced melanoma have BRAF mutation, and in some studies the mutation rate even reaches as high as 60%.88 Actually, the occurrence of BRAF mutations increases the risk of BM at first diagnosis of metastatic disease.89 It is well‐known that V600E is the most common mutation in BRAF which leads to the MAPK signaling pathway aberrantly activated.90 At the same time, the activation of many bypass pathways and transcription factors enable the progression of BM becoming more rapid and uncontrollable.